ABSTRACT
Less is known about the impact of non-hip non-vertebral fractures (NHNV) on early death. This study demonstrated increased risk of dying following hip and NHNV fractures which was further increased by a subsequent fracture. This highlights the importance of early intervention to prevent both initial and subsequent fractures and improve survival. INTRODUCTION: Osteoporotic fractures are a major health concern. Limited evidence exists on their impact on mortality in ageing populations. This study examined the contribution of initial fracture type and subsequent fracture on mortality in a Norwegian population that has one of the highest rates of fractures. METHODS: The Tromsø Study is a prospective population-based cohort in Norway. Women and men aged 50+ years were followed from 1994 to 2010. All incident hip and non-hip non-vertebral (NHNV) fractures were registered. NHNV fractures were classified as either proximal or distal. Information on self-reported co-morbidities, lifestyle factors, general health and education level was collected. Multivariable Cox models were used to quantify mortality risk with incident and subsequent fractures analysed as time-dependent variables. RESULTS: Of 5214 women and 4620 men, 1549 (30%) and 504 (11%) sustained a fracture, followed by 589 (38%) and 254 (51%) deaths over 10,523 and 2821 person-years, respectively. There were 403 (26%) subsequent fractures in women and 68 (13%) in men. Hip fracture was associated with a two-fold increase in mortality risk (HR 2.05, 95% CI 1.73-2.42 in women and 2.49, 95% CI 2.00-3.11 in men). Proximal NHNV fractures were associated with 49% and 81% increased mortality risk in women and men (HR 1.49, 95% CI 1.21-1.84 and 1.81, 95% CI 1.37-2.41), respectively. Distal NHNV fractures were not associated with mortality. Subsequent fracture was associated with 89% and 77% increased mortality risk in women and men (HR 1.89, 95% CI 1.52-2.35 and 1.77, 95% CI 1.16-2.71), respectively. CONCLUSION: Hip, proximal NHNV and subsequent fractures were significantly associated with increased mortality risk in the elderly, highlighting the importance of early intervention.
Subject(s)
Hip Fractures , Osteoporotic Fractures , Spinal Fractures , Aged , Female , Hip Fractures/etiology , Hip Fractures/mortality , Humans , Male , Middle Aged , Norway/epidemiology , Osteoporotic Fractures/etiology , Osteoporotic Fractures/mortality , Prospective Studies , Risk FactorsABSTRACT
Childhood fracture may predict persistent skeletal fragility, but it may also reflect high physical activity which is beneficial to bone development. We observe a difference in the relationship between previous fracture and bone outcome across physical activity level and sex. Further elaboration on this variation is needed. PURPOSE: Childhood fracture may be an early marker of skeletal fragility, or increased levels of physical activity (PA), which are beneficial for bone mineral accrual. This study investigated the association between a previous history of childhood fracture and adolescent bone mineral outcomes by various PA levels. METHODS: We recruited 469 girls and 492 boys aged 15-18 years to this study. We assessed PA levels by questionnaire and measured areal bone mineral density (aBMD) and bone mineral content (BMC) using dual-energy X-ray absorptiometry (DXA) at arm, femoral neck (FN), total hip (TH), and total body (TB) and calculated bone mineral apparent density (BMAD, g/cm3). Fractures from birth to time of DXA measurements were retrospectively recorded. We analyzed differences among participants with and without fractures using independent sample t test. Multiple linear regression was used to examine the association between fractures and aBMD and BMC measurements according to adolescent PA. RESULTS: Girls with and without a previous history of fracture had similar BMC, aBMD, and BMAD at all sites. In multiple regression analyses stratified by physical activity intensity (PAi), there was a significant negative association between fracture and aBMD-TH and BMC-FN yet only in girls reporting low PAi. There was a significant negative association between forearm fractures, BMAD-FN, and BMAD-arm among vigorously active boys. CONCLUSION: Our findings indicate a negative association between childhood fractures and aBMD/BMC in adolescent girls reporting low PAi. In boys, such an association appears only in vigorously active participants with a history of forearm fractures.
Subject(s)
Bone Density/physiology , Osteoporotic Fractures/physiopathology , Absorptiometry, Photon/methods , Adolescent , Child , Exercise/physiology , Female , Femur Neck/physiopathology , Health Surveys , Humans , Male , Norway/epidemiology , Osteoporotic Fractures/epidemiology , Retrospective Studies , Risk Factors , Sex FactorsSubject(s)
Ciliophora Infections/veterinary , Fish Diseases/parasitology , Zebrafish/immunology , Animals , Ciliophora Infections/immunology , Fish Diseases/immunology , Gene Expression , Hymenostomatida/immunology , Real-Time Polymerase Chain Reaction/veterinary , Zebrafish/genetics , Zebrafish/metabolismABSTRACT
Hepatocytes are responsive to mitogenic effects of several ligands acting via EGFR. Studying primary cultures of rat hepatocytes, we found that, as compared to EGF, HB-EGF had a markedly higher affinity of the EGFR, while AR and TGFα had lower affinity. HB-EGF was also more potent compared to the other growth factors regarding phosphorylation of EGFR, Shc, ERK1/2 and Akt. All ligands induced phosphorylation of ErbB2, indicating receptor heterodimerization. TGFα, despite having much lower receptor affinity, was about equally potent and efficacious as HB-EGF as a stimulator of DNA synthesis. In contrast, EGF had relatively high affinity but markedly lower efficacy in stimulation of DNA synthesis. The results suggest that amplifying and/or inhibitory mechanisms may modulate the mitogenic responses downstream of the initial signalling steps, and that this may affect the effects of the EGFR ligands differentially.
Subject(s)
DNA/biosynthesis , ErbB Receptors/metabolism , Hepatocytes/drug effects , Signal Transduction , Transforming Growth Factor alpha/pharmacology , Animals , Cells, Cultured , Hepatocytes/metabolism , Ligands , Male , Mitogen-Activated Protein Kinase 1/metabolism , Mitogen-Activated Protein Kinase 3/metabolism , Phosphorylation , Protein Binding , Protein Multimerization , Protein Processing, Post-Translational , Proto-Oncogene Proteins c-akt/metabolism , Rats , Rats, Wistar , Shc Signaling Adaptor Proteins/metabolismABSTRACT
Alternariol (AOH), a mycotoxin produced by Alternaria fungi, is frequently found as a contaminant in fruit and grain products. Here we examined if AOH could modify macrophage phenotype and inflammatory responses. In RAW 264.7 mouse macrophages AOH changed the cell morphology of from round to star-shaped cells, with increased levels of CD83, CD86, CD11b, MHCII and endocytic activity. TNFα and IL-6 were enhanced at mRNA-level, but only TNFα showed increased secretion. No changes were found in IL-10 or IL-12p40 expression. Primary human macrophages changed the cell morphology from round into elongated shapes with dendrite-like protrusions in response to AOH. The levels of CD83 and CD86 were increased, HLA-DR and CD68 were down-regulated and CD80, CD200R and CD163 remained unchanged. Increased secretion of TNFα and IL-6 were found after AOH exposure, while IL-8, IL-10 and IL-12p70 were not changed. Furthermore, AOH reduced macrophage endocytic activity and autophagosomes. AOH was also found to induce DNA damage, which is suggested to be linked to the morphological and phenotypical changes. Thus, AOH was found to change the morphology and phenotype of the two cell models, but either of them could be characterized as typical M1/M2 macrophages or as dendritic cells (DC).
Subject(s)
DNA Damage , Lactones/toxicity , Macrophages/drug effects , Mycotoxins/toxicity , Animals , Cell Cycle Checkpoints/drug effects , Cells, Cultured , Cytokines/metabolism , Female , Humans , Inflammation/chemically induced , Macrophages/immunology , Macrophages/metabolism , Macrophages/pathology , Mice , Phenotype , Reactive Oxygen Species/metabolismABSTRACT
BACKGROUND: Activation of the extracellular signal-regulated kinases ERK1 and ERK2 in hepatocytes by prostaglandin (PG)F2alpha was recently found to be inhibited by pertussis toxin (PTX) suggesting a role for Gi proteins. RESULTS: Targeting the Gi2alpha expression by a specific ribozyme inhibited the PGF2alpha -induced ERK1/2 activation in hepatocytes. On the other hand a non-cleaving form of the Gi2alpha ribozyme did not significantly decrease the ERK1/2 activation. In ribozyme-treated cells the Gi2alpha protein level was reduced, while the Gqalpha level was not affected thus confirming the specificity of the ribozyme. CONCLUSION: The present data suggest an important role of Gi2 in PGF2alpha -induced ERK1/2 signaling in hepatocytes.
Subject(s)
GTP-Binding Protein alpha Subunits, Gi-Go/physiology , Hepatocytes/enzymology , Mitogen-Activated Protein Kinase 1/metabolism , Mitogen-Activated Protein Kinases/metabolism , Proto-Oncogene Proteins/physiology , Animals , Cells, Cultured , Dinoprost/pharmacology , Enzyme Activation , Enzyme Inhibitors/pharmacology , GTP-Binding Protein alpha Subunit, Gi2 , GTP-Binding Protein alpha Subunits, Gi-Go/genetics , Hepatocytes/drug effects , Male , Mitogen-Activated Protein Kinase 3 , Pertussis Toxin/pharmacology , Proto-Oncogene Proteins/genetics , RNA, Catalytic/pharmacology , Rats , Rats, WistarABSTRACT
The hepatic carcinogen 2-acetylaminofluorene (AAF) exerts its effect as a tumor promoter by mitoinhibition of normal hepatocytes. Initiated cells proliferate selectively and develop into preneoplastic foci and subsequently into carcinomas. To study whether some of the mitoinhibitory effects of AAF could be attributed to an influence on intracellular signal transduction, growth factor signaling was studied in cultured hepatocytes from rats fed AAF for 7 d. Activation through the epidermal growth factor receptor (EGFR) was used to probe possible changes in downstream mitogenic signaling mechanisms. The proliferative response to epidermal growth factor (EGF), measured as proliferating cell nuclear antigen expression and thymidine incorporation, was almost completely inhibited in hepatocytes exposed to AAF. Neither EGFR protein levels nor EGF binding was notably altered in AAF-exposed hepatocytes as opposed to normal hepatocytes. The initial tyrosine phosphorylation of EGFR and downstream activation of Sos, Raf-1, and extracellular signal-regulated protein kinase (ERK) were similar in AAF-treated and control hepatocytes. Even though ERK phosphorylation was unaffected, a remarkable (80%) reduction of ERK nuclear accumulation was observed in AAF-exposed hepatocytes immediately after mitogen stimulation. EGFR tyrosine phosphorylation and downstream signaling lasted 6 h in control cells versus 2 h in AAF-exposed hepatocytes. We previously demonstrated that AAF inhibits the growth factor-dependent induction of cyclin D1 and arrests hepatocyte cell-cycle progression before the p21/CIP1-controlled DNA-damage check point. The present data indicate that the DNA-damaging carcinogen AAF induces growth inhibition by a distinct inhibition of ERK nuclear accumulation after mitogen stimulation. Inhibition of intracellular signal transduction may represent a novel mechanism of growth arrest. Mol. Carcinog. 28:84-96, 2000.
Subject(s)
2-Acetylaminofluorene/pharmacology , Carcinogens/pharmacology , Cell Nucleus/enzymology , Epidermal Growth Factor/pharmacology , Liver/drug effects , Mitogen-Activated Protein Kinases/metabolism , Animals , Cell Division/drug effects , Cells, Cultured , ErbB Receptors/metabolism , Liver/enzymology , Phosphorylation , Protein Binding , RatsABSTRACT
It was previously found that pertussis toxin (PTX) pretreatment inhibits the activation of extracellular signal-regulated kinases ERK1 (p44(mapk)) and ERK2 (p42(mapk)) in hepatocytes in response to either agonists that bind to heptahelical receptors or epidermal growth factor (EGF), suggesting a role of G(i) proteins in stimulatory mechanisms for ERK1/2. The present work shows that ERK1/2 is activated in a PTX-sensitive way not only by vasopressin, angiotensin II, prostaglandin (PG) F(2alpha), alpha(1)-adrenergic stimulation, and EGF but also by agents whose actions bypass receptors and stimulate protein kinase C (PKC) and/or elevate intracellular Ca(2+), such as 12-O-tetradecanoyl phorbol-13-acetate (TPA), exogenous phosphatidylcholine-specific phospholipase C (PC-PLC, from Bacillus cereus), thapsigargin, and the Ca(2+) ionophore A23187. Under the same conditions, PTX did not affect agonist stimulation of phosphoinositide-specific phospholipase C (PI-PLC) (IP(3) generation), and did not reduce the activation by these agents of phospholipase D (PLD). The results suggest that in hepatocytes a PTX-sensitive mechanism, presumably involving G(i) proteins, exerts a stimulatory effect on ERK at a level distal to receptor coupling, acting either as an integral part of the signaling pathway(s) or by a permissive, synergistic regulation.
Subject(s)
Angiotensin II/pharmacology , ErbB Receptors/physiology , GTP-Binding Protein alpha Subunits, Gi-Go/metabolism , Liver/drug effects , Mitogen-Activated Protein Kinase 1/metabolism , Mitogen-Activated Protein Kinases/metabolism , Pertussis Toxin , Vasopressins/pharmacology , Virulence Factors, Bordetella/pharmacology , Animals , Calcimycin/pharmacology , Cell Division/drug effects , Cells, Cultured , Dinoprost/pharmacology , Enzyme Activation , Epidermal Growth Factor/pharmacology , ErbB Receptors/drug effects , Inositol 1,4,5-Trisphosphate/metabolism , Liver/cytology , Liver/metabolism , Male , Mitogen-Activated Protein Kinase 3 , Norepinephrine/pharmacology , Phosphatidylinositol Diacylglycerol-Lyase , Phosphoinositide Phospholipase C , Phospholipase D/metabolism , Rats , Rats, Wistar , Receptors, Adrenergic, alpha-1/physiology , Thapsigargin/pharmacology , Type C Phospholipases/metabolismABSTRACT
Previous studies have indicated that cAMP has bidirectional effects on epidermal growth factor (EGF)-induced DNA synthesis in cultured hepatocytes, acting to stimulate soon after plating (early G(1)) and to inhibit at later stages (nearer the G(1)/S transition). In this study we examined the role of the extracellular signal-regulated kinase (ERK) subgroup (p42/p44) of the mitogen activated protein (MAP) kinases both at growth-stimulatory and growth-inhibitory conditions. When added at low concentrations early during culturing, glucagon and 8-chlorophenylthio-cAMP (8-CPT-cAMP) did not increase MAP kinase activity, but enhanced the subsequent DNA synthesis. However, when administered at 24 h, glucagon and 8-CPT-cAMP decreased basal and EGF-induced MAP kinase activity and also inhibited EGF-induced DNA synthesis. Thus, although MAP kinase might play a role in the growth-inhibitory effect, it does not seem to be involved in growth-promoting regulation by cAMP in hepatocytes.
Subject(s)
Cyclic AMP/pharmacology , DNA/biosynthesis , Liver/metabolism , Mitogen-Activated Protein Kinase 1/metabolism , Mitogen-Activated Protein Kinases/metabolism , Signal Transduction , Animals , Cells, Cultured , MAP Kinase Signaling System/drug effects , Male , Mitogen-Activated Protein Kinase 3 , Rats , Rats, Wistar , Signal Transduction/drug effectsABSTRACT
The role of diacylglycerol (DAG) in hormonal induction of S phase was investigated in primary cultures of rat hepatocytes. In this model, several agonists that bind to G protein-coupled receptors act as comitogens when added to the cells soon after plating (i.e., in Go/early Gl phase), while the cells are most responsive to the mitogenic effect of epidermal growth factor (EGF) at 24-48 h of culturing (i.e., mid/late Gl). It was found that the cellular concentration of DAG rose markedly and progressively during the first 24 h of culturing. Exposure of the hepatocytes at 3 h to alpha1-adrenergic stimulation (norepinephrine with timolol), vasopressin, or angiotensin II further increased this rise, producing a sustained increase in the DAG level. Norepinephrine, which was the most efficient comitogen, produced the most prolonged DAG elevation. In contrast, no significant increase of DAG was found in response to EGF, neither at 3 nor at 24 h, using concentrations that markedly stimulated the ERK subgroup of the mitogen-activated protein kinases (MAPK) and DNA synthesis. Addition of Bacillus cereus phosphatidylcholine-specific phospholipase C (PC-PLC) strongly elevated DAG, while Streptomyces phospholipase D (PLD) increased phosphatidic acid (PA) but not DAG. B. cereus PC-PLC and the protein kinase C (PKC) activator tetradecanoyl phorbol-acetate (TPA), like norepinephrine, vasopressin, and angiotensin II, stimulated MAPK and enhanced the stimulatory effect of EGF on DNA synthesis. The PKC inhibitor GF109203X did not diminish the effect of EGF on MAPK or DNA synthesis, but strongly inhibited the effects of norepinephrine, vasopressin, angiotensin II, TPA and B. cereus PC-PLC on MAPK and almost abolished the enhancement by these agents of EGF-stimulated DNA synthesis. These results suggest that although generation of DAG is not a direct downstream response mediating the effects of the EGF receptor in hepatocytes, a sustained elevation of DAG with activation of PKC markedly increases the responsiveness to EGF. Mechanisms involving DAG and PKC seem to play a role in the comitogenic effects of various agents that bind to G protein-coupled receptors and activate the cells early in Gl, such as norepinephrine, angiotensin II, and vasopressin.
Subject(s)
Diglycerides/metabolism , Epidermal Growth Factor/pharmacology , Neuropeptides/pharmacology , Protein Kinase C/metabolism , S Phase/physiology , Angiotensin II/pharmacology , Animals , Bacterial Proteins/pharmacology , Calcium-Calmodulin-Dependent Protein Kinases/antagonists & inhibitors , Calcium-Calmodulin-Dependent Protein Kinases/metabolism , Carcinogens/pharmacology , Cells, Cultured , DNA/biosynthesis , Enzyme Activation/physiology , Enzyme Inhibitors/pharmacology , G1 Phase/drug effects , G1 Phase/physiology , GTP-Binding Proteins/metabolism , Indoles/pharmacology , Liver/cytology , Liver/enzymology , Male , Maleimides/pharmacology , Norepinephrine/pharmacology , Phospholipase D/metabolism , Phospholipase D/pharmacology , Protein Kinase C/antagonists & inhibitors , Protein Kinase C/pharmacology , Rats , Rats, Wistar , S Phase/drug effects , Tetradecanoylphorbol Acetate/pharmacology , Vasopressins/pharmacologyABSTRACT
cAMP positively and negatively regulates hepatocyte proliferation but its molecular targets are still unknown. Cyclin A2 is a major regulator of the cell cycle progression and its synthesis is required for progression to S phase. We have investigated whether cyclin A2 and cyclin A2-associated kinase might be one of the targets for the cAMP transduction pathway during progression of hepatocytes through G1 and G1/S. We show that stimulation of primary cultured hepatocytes by glucagon differentially modulated the expression of G1/S cyclins. Glucagon indeed upregulated cyclin A2 and cyclin A2-associated kinase while cyclin E-associated kinase was unmodified. In conclusion, our study identifies cyclin A2 as an important effector of the cAMP transduction network during hepatocyte proliferation.
Subject(s)
Cyclic AMP/metabolism , Cyclin A/metabolism , G1 Phase , Liver/metabolism , S Phase , Animals , Blotting, Western , Cell Division/drug effects , Cells, Cultured , Cyclin A2 , Cyclin-Dependent Kinases/metabolism , Cyclins/metabolism , DNA/biosynthesis , G1 Phase/drug effects , Glucagon/pharmacology , Liver/cytology , Liver/drug effects , Male , Rats , Rats, Wistar , S Phase/drug effects , Signal Transduction/drug effects , Time Factors , Up-Regulation/drug effectsABSTRACT
Previous studies have shown that while vasopressin and angiotensin II are markedly more effective than norepinephrine and prostaglandin F2alpha in eliciting an acute elevation of inositol 1,4,5-trisphosphate (IP3), norepinephrine and prostaglandin F2alpha produce larger enhancement of DNA synthesis. This suggests that the initial activation of phosphoinositide-specific phospholipase C is not a common factor for the growth response to these agonists, but does not exclude a role of the integral of phospholipase C activity over a prolonged part of the prereplicative period, during which agonist-specific changes in responsiveness might occur. We show that vasopressin and angiotensin II also cause a prolonged elevation of cellular IP3 levels. which remain elevated for at least 60 min., while norepinephrine and prostaglandin F2alpha elevate IP3 levels slightly and transiently For vasopressin the dose-effect curves for IP3 accumulation and stimulation of DNA synthesis were closely parallel, while this was not the case for angiotensin II, norepinephrine, or prostaglandin F2alpha. After cultivation of the hepatocytes, hormone-stimulated IP3 accumulation rapidly declined, particularly in response to norepinephrine and prostaglandin F2alpha. When the IP3 response to norepinephrine and prostaglandin F2alpha was completely down-regulated, these agonists still enhanced the DNA synthesis. These results suggest that other mechanisms in addition to IP3 accumulation and Ca2+ release are likely to be involved in the growth stimulatory effects of the Ca2+-mobilizing agonists studied here, in particular for angiotensin II, norepinephrine, and prostaglandin F2alpha.
Subject(s)
Calcium Signaling/drug effects , Inositol 1,4,5-Trisphosphate/metabolism , Liver/drug effects , Phosphatidylinositols/metabolism , Type C Phospholipases/metabolism , Angiotensin II/pharmacology , Animals , Cell Division/drug effects , Cells, Cultured , DNA/biosynthesis , DNA/drug effects , Dinoprost/pharmacology , Down-Regulation , Enzyme Activation , Liver/cytology , Liver/metabolism , Male , Norepinephrine/pharmacology , Rats , Rats, Wistar , Time Factors , Vasopressins/pharmacologyABSTRACT
Transcription factors of the STAT family have been implicated in regulation of cell proliferation. EGF activates several STAT proteins in liver. We have studied the relationship between STAT activation and the growth-stimulatory effect of EGF in rat hepatocytes, assessing specific DNA-binding activity of STAT proteins in electrophoretic mobility-shift and supershift assays. In freshly isolated hepatocytes, EGF activated Stat1, Stat3, and, particularly, Stat5b. However, the ability of EGF to produce this activation was rapidly attenuated when the cells were cultured, while the activation by IFN-gamma (Stat1) and IL-6 (Stat3) was sustained. Hepatocytes cultured for 24-48 h are highly sensitive to the stimulatory effect of EGF on S phase entry. In these cells EGF did not detectably activate Stat1, Stat3, or Stat5b but markedly stimulated MAP kinase (Erk1/2). Thus, although EGF has the ability to activate several STAT proteins, this did not seem to be part of the mitogenic mechanisms used by the EGF receptor in hepatocytes.
Subject(s)
DNA Replication/drug effects , DNA-Binding Proteins/metabolism , Epidermal Growth Factor/pharmacology , Liver/drug effects , Milk Proteins , Trans-Activators/metabolism , Animals , Base Sequence , Calcium-Calmodulin-Dependent Protein Kinases/metabolism , Cells, Cultured , DNA Primers , G1 Phase/drug effects , Interferon-gamma/pharmacology , Interleukin-2/pharmacology , Liver/cytology , Liver/metabolism , Male , Rats , Rats, Wistar , STAT1 Transcription Factor , STAT3 Transcription Factor , STAT5 Transcription FactorABSTRACT
2-Acetylaminofluorene (AAF) is a potent tumor promoter in rat liver carcinogenesis models. In the resistant hepatocyte model, AAF is combined with a growth stimulus for efficient promotion of preneoplastic lesions. The promoting property of AAF in this model is closely associated with mito-inhibition of normal hepatocytes, an effect to which initiated cells are resistant. How AAF induces growth arrest is not known, but genotoxic as well as non-genotoxic effects have been implicated. To elucidate the mechanisms of AAF-induced mito-inhibition, we studied the expression of the tumor suppressor protein p53 and the cyclin-dependent kinase (cdk) complexes mediating G1 progression and S-phase entry. Hepatocytes were isolated from male Fisher 344 rats fed either a control diet or a diet supplemented with 0.02% AAF for 1 wk and cultured in a defined serum-free medium containing epidermal growth factor, insulin, and dexamethasone. Thymidine labeling revealed a profound inhibition of DNA synthesis in AAF-exposed cells compared with control cells. The retinoblastoma protein did not become hyperphosphorylated in AAF-exposed cells. Thus, inhibition of G1 cyclin-cdk activity was implied as a cause of growth arrest. Indeed, G1 cell-cycle arrest was accompanied by reduced induction and nuclear accumulation of the cyclin D1-cdk4 complex and inhibited nuclear translocation of cdk2. Furthermore, the growth arrest was not mediated through p21/waf1 upregulation, although nuclear levels of p53 were increased. Thus, carcinogen-induced mito-inhibition may be effected by altered levels and localization of G1 cyclin-cdk complexes, independent of the upregulation of cdk inhibitory proteins.
Subject(s)
2-Acetylaminofluorene/pharmacology , Carcinogens/pharmacology , Cell Cycle/genetics , Cyclins/genetics , Gene Expression Regulation/drug effects , Genes, p53 , Liver/drug effects , Animals , Cell Division/drug effects , Cells, Cultured , Culture Media, Serum-Free , Cyclin-Dependent Kinase Inhibitor p21 , Cyclins/biosynthesis , DNA/biosynthesis , Enzyme Inhibitors , G1 Phase , Kinetics , Liver/cytology , Liver/metabolism , Male , Rats , Rats, Inbred F344 , Thymidine/metabolism , Time Factors , Tumor Suppressor Protein p53/biosynthesisABSTRACT
We investigated the ability of endocytosed activated epidermal growth factor receptors (EGFR) to induce expression of the cyclin-interacting protein p21/CIP1 in A431 cells. Transforming growth factor alpha (TGFalpha) and EGF both induced tyrosine phosphorylation, induction of p21/CIP1, and thereby inhibition of DNA synthesis. TGFalpha is released from the EGFR when the TGFalpha-EGFR complex encounters low pH upon endocytosis. Consistently, we found more rapid dephosphorylation of the EGFR and less induction of p21/CIP1 by TGFalpha than by EGF. This difference was abolished upon neutralizing endosomal pH by the carboxylic ionophore monensin or the proton ATPase inhibitor bafilomycin A1. When surface-bound TGFalpha was removed by acid stripping and endosomal pH was neutralized with bafilomycin A1, TGFalpha stimulated EGFR tyrosine phosphorylation, induced p21/CIP1, and inhibited DNA synthesis. This strongly suggests that p21/CIP1 can be induced by endocytosed, activated EGFR and that endocytosed EGFR can affect cell growth.
Subject(s)
Cyclins/metabolism , Epidermal Growth Factor/pharmacology , ErbB Receptors/metabolism , Macrolides , Anti-Bacterial Agents/pharmacology , Calcium-Calmodulin-Dependent Protein Kinases/metabolism , Cell Division , Cyclin-Dependent Kinase Inhibitor p21 , DNA/biosynthesis , Endocytosis , Enzyme Inhibitors/metabolism , Enzyme Inhibitors/pharmacology , Humans , Hydrogen-Ion Concentration , Microscopy, Fluorescence , Monensin/pharmacology , Phosphorylation , Time Factors , Transforming Growth Factor alpha/pharmacology , Tumor Cells, CulturedABSTRACT
Several agents that act through G-protein-coupled receptors and also stimulate phosphoinositide-specific phospholipase C (PI-PLC), including angiotensin II, vasopressin, norepinephrine, and prostaglandin (PG) F2alpha, activated the ERK1 (p44mapk) and ERK2 (p42mapk) members of the mitogen-activated protein (MAP) kinase family in primary cultures of rat hepatocytes, measured as phosphorylation of myelin basic protein (MBP) by a partially purified enzyme, immunoblotting, and in-gel assays. All these agonists induced a peak activation (two to threefold increase in MBP-phosphorylation) at 3-5 min, followed by a brief decrease, and then a sustained elevation or a second increase of the MAP kinase activity that lasted for several hours. Although all the above agents also stimulated PI-PLC, implicating a Gq-dependent pathway, the elevations of the concentration of inositol (1,4,5)-trisphosphate did not correlate well with the MAP kinase activity. Furthermore, pretreatment of the cells with pertussis toxin markedly reduced the MAP kinase activation by angiotensin II, vasopressin, norepinephrine, or PGF2alpha. In addition, hepatocytes pretreated with pertussis toxin showed a diminished MAP kinase response to epidermal growth factor (EGF). The results indicate that agonists acting via G-protein-coupled receptors have the ability to induce sustained activation of MAP kinase in hepatocytes, and suggest that Gi-dependent mechanisms are required for full activation of the MAP kinase signal transduction pathway by G-protein-coupled receptors as well as the EGF receptor.
Subject(s)
Dinoprost/pharmacology , GTP-Binding Protein alpha Subunits, Gi-Go/physiology , Liver/enzymology , Mitogen-Activated Protein Kinase 1/metabolism , Neuropeptides/pharmacology , Norepinephrine/pharmacology , Animals , Cells, Cultured , DNA/biosynthesis , Enzyme Activation , Epidermal Growth Factor/pharmacology , Inositol 1,4,5-Trisphosphate/analysis , Liver/cytology , Male , Pertussis Toxin , Rats , Rats, Wistar , Time Factors , Virulence Factors, Bordetella/pharmacologyABSTRACT
The epidermal growth factor (EGF) receptor mediates the effects of both EGF and transforming growth factor alpha (TGFalpha). Recent data suggested that EGF acts as a partial agonist/antagonist in hepatocytes, TGFalpha exerting a larger maximal stimulation of DNA synthesis than EGF. To further study the mechanisms involved in mediating the different effects of EGF and TGFalpha, we have examined receptor binding of the two growth factors and their action on the p42/p44 mitogen-activated protein (MAP) kinase activity in hepatocytes. Single-ligand concentration curves and competition experiments showed that the binding affinity to a common population of surface binding sites was about 20-fold lower for TGFalpha than for EGF. MAP kinase activity responded to EGF and TGFalpha with different kinetics. While the two agents produced almost identical acute (5 min) stimulation (peak about fivefold), TGFalpha produced a more sustained MAP kinase activity than EGF. The difference between EGF and TGFalpha was still detectable 24 h after growth factor addition. The results show that in hepatocytes a lower receptor affinity of TGFalpha, as compared to EGF, is associated with a more sustained activation of the MAP kinase and a greater efficacy in the stimulation of DNA synthesis. This suggests that differential interaction of these two agents with the EGF receptor results in differences in the downstream events elicited at a given level of receptor occupancy. The data also are compatible with a role of a prolonged MAP kinase activity in the mitogenic effects of EGF and TGFalpha.
Subject(s)
Calcium-Calmodulin-Dependent Protein Kinases/metabolism , Epidermal Growth Factor/pharmacology , ErbB Receptors/physiology , Mitogen-Activated Protein Kinase 1/metabolism , Mitogen-Activated Protein Kinases , Transforming Growth Factor alpha/pharmacology , Animals , Binding, Competitive/drug effects , Cells, Cultured , DNA/biosynthesis , Dose-Response Relationship, Drug , Drug Interactions , Enzyme Activation , Liver/chemistry , Liver/cytology , Liver/enzymology , Male , Mitogen-Activated Protein Kinase 3 , Rats , Rats, Wistar , Time FactorsABSTRACT
OBJECTIVE: To study if the Tono-Pen, a hand held digital tonometer, can replace Schiøtz tonometry in general practice. DESIGN: Tonometry with Tono-Pen and Schiøtz tonometer were compared. SETTING: Group practice with two general practitioners (GPs). PATIENTS: 48 consecutive patients over 40 years of age. MAIN OUTCOME MEASURES: The mean difference between intra ocular pressure (IOP) measured with the two methods with 95% confidence intervals and 95% limits of agreement between them. RESULTS: One observer found a mean difference between methods of 0.3 mmHg and 95% limits of agreement of +/- 4 mmHg. The other observer with a different Schiøtz tonometer, had a mean difference of approximately -2 mmHg and 95% limits of agreement from -8 to +4 mmHg. CONCLUSION: We consider the Tono-Pen to be an alternative to Schiøtz tonometry. The maximum mean difference between the methods for one GP, 1.9 mmHg, was within clinically acceptable limits. Possible reasons for the different agreement for the two observers are discussed.
Subject(s)
Family Practice , Glaucoma/diagnosis , Intraocular Pressure , Tonometry, Ocular/instrumentation , Female , Follow-Up Studies , Humans , Male , Middle Aged , Observer Variation , Referral and Consultation , Reproducibility of Results , Tonometry, Ocular/standardsABSTRACT
Although several hormones that promote hepatocyte proliferation also activate phosphoinositide-specific phospholipase C (PI-PLC) and mobilize Ca2+, the role of PI-PLC in the growth-stimulating effect of these agents is not clear. We have investigated this issue further, by exposing freshly isolated adult rat hepatocytes to vasopressin, angiotensin II, norepinephrine (in the presence of the beta-adrenoceptor blocker timolol) or PGF2 alpha, and examined both acute responses and the subsequent DNA synthesis when the cells were grown in monolayer culture. All the agonists elevated the level of inositol 1,4,5-trisphosphate (InsP3) and enhanced the DNA synthesis, amplifying the response to epidermal growth factor (EGF), and this comitogenic effect could be exerted by a single exposure of the cells 24 h prior to the addition of EGF. The acute activation of PI-PLC, measured as the early rise (peak 15-60 s) in InsP3, was 8-10-fold with vasopressin or angiotensin II, 3-4-fold with norepinephrine, and approximately 2-fold with PGF2 alpha. For all the agonists, a rise in cytosolic free Ca2+ in 100% of the cells and a maximal increase in glycogen phosphorylase activity were evoked at concentrations that approximately doubled the level of InsP3. However, the growth-stimulatory effects of these agonists showed a different order of efficacy as compared to the activation of PI-PLC; in terms of the maximal stimulation of DNA synthesis, the effects were: norepinephrine approximately PGF2 alpha > angiotensin II > vasopressin. Also, norepinephrine, PGF2 alpha, and angiotensin II, but not vasopressin, further enhanced the DNA synthesis when their concentrations were increased above those yielding maximal elevation of InsP3. In experiments where vasopressin and angiotensin II were combined, their effects on the DNA synthesis were additive while the InsP3 responses were not. The results show that the extent of the initial activation of PI-PLC is not the determinant for the magnitude of the growth effects of Ca(2+)-mobilizing hormones in hepatocytes. This suggests either (a) that the proliferative response to these agents is determined by the activity of PI-PLC at a later time, or its integral over an extended part of the prereplicative period, rather than by the acute activation, or (b) that additional, PI-PLC-independent, mechanisms are required.
Subject(s)
Angiotensin II/pharmacology , Calcium/physiology , Cell Division , Dinoprost/pharmacology , Inositol 1,4,5-Trisphosphate/metabolism , Liver/cytology , Norepinephrine/pharmacology , Phosphoric Diester Hydrolases/metabolism , Vasopressins/pharmacology , Animals , Cell Division/drug effects , DNA/biosynthesis , Enzyme Activation/drug effects , Epidermal Growth Factor/pharmacology , Male , Phosphatidylinositol Diacylglycerol-Lyase , Phosphoinositide Phospholipase C , Phosphorylases/metabolism , Rats , Rats, Wistar , Second Messenger Systems , Time FactorsABSTRACT
Addition of 8-bromo-adenosine 3',5'-cyclic monophosphate (8-bromo-cAMP) or 8-(4-chlorophenylthio)-adenosine 3',5'-cyclic monophosphate (8-CPT-cAMP) to hepatocytes at the time of plating enhanced the acquisition of beta-adrenoceptors that occurs spontaneously upon culturing as primary monolayers. This effect was partially suppressed by the phosphodiesterase inhibitor isobutyl methylxanthine, and was mimicked by 8-bromo-AMP, 8-bromo-adenosine, and the adenosine kinase inhibitor 5'-amino-5'-deoxyadenosine. Agents that elevated the intracellular level of cAMP, such as glucagon and forskolin, and Sp-8-bromo-adenosine 3',5'-monophosphorothioate (Sp-8-bromo-cAMPS), a cAMP analogue that is resistant towards metabolic breakdown, did not significantly enhance beta-adrenoceptor expression when used alone, but glucagon enhanced the effect of 8-bromo-adenosine. 8-bromo-cAMP and 8-bromo-adenosine decreased cellular ATP-levels. These observations suggest that the enhanced beta-adrenoceptor acquisition was mediated mainly through the action of metabolites of 8-bromo-cAMP and 8-CPT-cAMP, although there may be a cAMP-mediated component in the effect. Several mechanisms, including depletion of ATP, are probably involved, and might affect beta-adrenoceptor degradation.